EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN‐035

José Bauermeister iD, Willey Lin, Ryan Tingler, Albert Liu iD, Suwat Chariyalertsak, Craig Hoesley, Pedro Gonzales, Ken Ho, Noel Kayange, Thesla Palanee Phillips iD, Sherri Johnson, Elizabeth Brown iD und 5 weitere

Journal of the International AIDS Society · 2024

DOI: 10.1002/jia2.26219 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the International AIDS Society, 2024. Verfasst von José Bauermeister und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anti-Infective Agents, HIV Infections, Sexual and Gender Minorities. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIMH NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

End‐user perspectives are vital to the design of new biomedical HIV prevention products. Conjoint analysis can support the integration of end‐user perspectives by examining their preferences of potential pre‐exposure prophylaxis (PrEP) products. The Microbicides Trial Network (MTN) 035 protocol examined three placebo rectal dosage forms (insert, enema and suppository) that could deliver PrEP prior to receptive anal sex (RAS).

Methods

Between April 2019 and July 2020, we enrolled 217 HIV‐negative, cisgender men who have sex with men (MSM; n = 172; 79.3%) and transgender people ( n = 47; 20.7%) ages 18–35 into a randomized cross‐over trial across Malawi, Peru, South Africa, Thailand and the United States. Participants used each product prior to RAS over 4‐week periods. Participants completed a conjoint experiment where they selected between random profiles using seven features (dosage form, timing of use before sex, side effects, duration of protection, effectiveness, frequency of use and need for a prescription).

Results

Effectiveness was the strongest determinant of choice (30.4%), followed by modality (18.0%), potential side effects (17.2%), frequency of use (10.8%), duration of protection (10.4%), timing of use before sex (7.4%) and need for a prescription (5.9%). Relative utility scores indicated that the most desirable combination of attributes was a product with 95% efficacy, used 30 minutes before sex, offering a 3‐ to 5‐day protection window, used weekly, having no side effects, in the form of an enema and available over‐the‐counter.

Conclusions

Choice in next‐generation PrEP products is highly desired by MSM and transgender people, as no one‐size‐fits‐all approach satisfies all the preferences. MTN‐035 participants weighed product features differently, recognizing the need for diverse, behaviourally congruent biomedical options that fit the needs of intended end‐users.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Infective AgentsHIV InfectionsSexual and Gender MinoritiesHumansMaleHomosexuality, MaleSexual BehaviorUnited StatesFemaleAdolescentYoung AdultAdult

Stichwörter der Autor:innen

HIV preventionPrEPacceptabilitymen who have sex with menmicrobicidestransgender

Substanzen

Anti-Infective Agents

Autor:innen und Institutionen

  • University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Bridge HIV at the San Francisco Department of Public Health, San Francisco, California, USA.
  • Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • IMPACTA, Asociación Civil Impacta Salud y Educación, San Miguel CRS, Lima, Perú.
  • University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: José Bauermeister, Albert Liu, Thesla Palanee Phillips, Elizabeth Brown

Förderung

  • NIAID NIH HHS
  • NIMH NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Child Health and Human Development
  • National Institute of Mental Health
  • National Institutes of Health
  • United States Agency for International Development

Zitieren

APA

Bauermeister, J., Lin, W., Tingler, R., Liu, A., Chariyalertsak, S., Hoesley, C., Gonzales, P., Ho, K., Kayange, N., Phillips, T. P., Johnson, S., Brown, E., Zemanek, J., Jacobson, C. E., Doncel, G. F., Piper, J., & MTN-035 Protocol Team for the Microbicide Trials Network (2024). A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN‐035. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26219

Vancouver

Bauermeister J, Lin W, Tingler R, Liu A, Chariyalertsak S, Hoesley C, et al. A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN‐035. Journal of the International AIDS Society. 2024. doi:10.1002/jia2.26219

BibTeX
@article{Bauermeister2024,
  author = {Bauermeister, José and Lin, Willey and Tingler, Ryan and Liu, Albert and Chariyalertsak, Suwat and Hoesley, Craig and Gonzales, Pedro and Ho, Ken and Kayange, Noel and Phillips, Thesla Palanee and Johnson, Sherri and Brown, Elizabeth and Zemanek, Jillian and Jacobson, Cindy E and Doncel, Gustavo F and Piper, Jeanna and MTN-035 Protocol Team for the Microbicide Trials Network, MTN-035 Protocol Team for the Microbicide Trials Network},
  title = {A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN‐035},
  journal = {Journal of the International AIDS Society},
  year = {2024},
  doi = {10.1002/jia2.26219}
}
Kostenlos starten →